Type 2 Diabetes
Conditions
Keywords
Exercise, Walking, Type 2 diabetes, Therapy
Brief summary
The purpose of the study is to evaluate the impact of an exercise programme organized into supervised walking groups on metabolic control, functional capacity and overall quantity of physical activity in subjects with type 2 diabetes.
Detailed description
Regular, moderate-intensity physical activity can attenuate hyperglycemia in subjects with type 2 diabetes. In addition, these programmes may favourably affect several other cardiovascular risk factors in these subjects. However, it still remains unclear how this evidence can be transferred into clinical practice, considering the very large number of diabetic patients and the characteristics of this population, made up predominantly of elderly, sedentary and overweight patients. In this regard, a realistic approach to this issue requires simple and easily available intervention models. Walking is a typical mild-moderate aerobic physical activity which is easy to organize and does not require specific skills or preliminary sophisticated medical evaluations. This activity could therefore fit well with the need of involvement of large numbers of patients in different logistic situations. However, it has been reported that, due to the low walking speed typical of type 2 diabetic subjects, self-paced walking is inadequate to obtain a significant metabolic improvement in these subjects.
Interventions
BEHAVIORALSupervised walking
Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
BEHAVIORALStandard counselling procedure
Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
Sponsors
Universita di Verona
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* diabetes known for at least 2 yr * physical inactivity * haemoglobin (Hb)A1c between 6.5-9.9% * treatment with oral hypoglycaemic agents alone or associated with a bed-time insulin injection * willingness to participate in a programme of regular physical activity
Exclusion criteria
* moderate-severe autonomic or somatic neuropathy * severe lower limb vasculopathy * pre-proliferative or proliferative active retinopathy * moderate to severe chronic renal failure * unstable angina or recent (in the previous 3 months) myocardial infarction * acute intercurrent diseases * acute metabolic decompensation (blood glucose \>300 mg/dl or ketonuria in two consecutive checks) * use of beta-blocker drugs * subjects unable to complete a 6-min walk test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in haemoglobin A1c (HbA1c) levels | 4 months | The measurement of HbA1c is carried out with a DCCT-aligned method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Blood Pressure | 4 months | — |
| Change in Body weight | 4 months | — |
| Change in Fasting plasma glucose levels | 4 months | — |
| Change in Total Cholesterol levels | 4 months | — |
| Change in HDL Cholesterol levels | 4 months | — |
| Change in Triglycerides levels | 4 months | — |
| Change in 6 minutes walk distance | 4 months | This test measures the number of meters that can be walked in 6 minutes over a 30 m course. It is a simple field test to assess aerobic functional capacity. |
| Change in C-reactive protein levels | 4 months | — |
| Change in Energy expenditure through voluntary physical activity | 4 months | Energy expenditure is estimated through 7-day activity diaries. The intensity of each activity (defined in metabolic equivalents, MET) is multiplied by duration and the product for each activity is summed to give a total activity score in MET hours/week. |
| Change in Antidiabetic medications | 4 months | Class and dosage of blood-glucose lowering drugs are recorded before and at the end of the protocol, to assess changes in hypoglycemic medication during the trial. |
| Compliance with walking sessions | 4 months | Attendance at the scheduled walking sessions is recorded for each patient. |
| Change in LDL Cholesterol levels | 4 months | — |
Outcome results
None listed